Scinai Immunotherapeutics Ltd (SCNI) FinancialsSCNIScinai Immunotherapeutics Ltd

Evaluating the bottom line, Scinai Immunotherapeutics Ltd maintains a gross margin of -228.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -504.50%, while the net margin is 731.49%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SCNI converts its operational activities into shareholder value.

In the context of the broader market, SCNI competes directly with industry leaders such as SNYR and ATPC. With a market capitalization of $1.25M, it holds a significant position in the sector. When comparing efficiency, SCNI's gross margin of -228.63% stands against SNYR's 71.69% and ATPC's 85.96%. Such benchmarking helps identify whether Scinai Immunotherapeutics Ltd is trading at a premium or discount relative to its financial performance.

The company has shown volatility in its financial performance, with total revenue for Q1 2026 at $0.4 million and a significant net income of $3.6 million, primarily due to a non-cash gain. However, gross margins are concerning, with a negative figure of -228.63% in Q1 2026, indicating challenges in profitability.